Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan.

Vennin C, Mélénec P, Rouet R, Nobis M, Cazet AS, Murphy KJ, Herrmann D, Reed DA, Lucas MC, Warren SC, Elgundi Z, Pinese M, Kalna G, Roden D, Samuel M, Zaratzian A, Grey ST, Da Silva A, Leung W; Australian Pancreatic Genome Initiative (APGI), Mathivanan S, Wang Y, Braithwaite AW, Christ D, Benda A, Parkin A, Phillips PA, Whitelock JM, Gill AJ, Sansom OJ, Croucher DR, Parker BL, Pajic M, Morton JP, Cox TR, Timpson P.

Nat Commun. 2019 Aug 12;10(1):3637. doi: 10.1038/s41467-019-10968-6.

2.

Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer.

Kennedy SP, Han JZR, Portman N, Nobis M, Hastings JF, Murphy KJ, Latham SL, Cadell AL, Miladinovic D, Marriott GR, O'Donnell YEI, Shearer RF, Williams JT, Munoz AG, Cox TR, Watkins DN, Saunders DN, Timpson P, Lim E, Kolch W, Croucher DR.

Breast Cancer Res. 2019 Mar 21;21(1):43. doi: 10.1186/s13058-019-1127-y.

3.

Inhibition of activin signaling in lung adenocarcinoma increases the therapeutic index of platinum chemotherapy.

Marini KD, Croucher DR, McCloy RA, Vaghjiani V, Gonzalez-Rajal A, Hastings JF, Chin V, Szczepny A, Kostyrko K, Marquez C, Jayasekara WSN, Alamgeer M, Boolell V, Han JZR, Waugh T, Lee HC, Oakes SR, Kumar B, Harrison CA, Hedger MP, Lorensuhewa N, Kita B, Barrow R, Robinson BW, de Kretser DM, Wu J, Ganju V, Sweet-Cordero EA, Burgess A, Martelotto LG, Rossello FJ, Cain JE, Watkins DN.

Sci Transl Med. 2018 Jul 25;10(451). pii: eaat3504. doi: 10.1126/scitranslmed.aat3504.

PMID:
30045976
4.

Dissecting Multi-protein Signaling Complexes by Bimolecular Complementation Affinity Purification (BiCAP).

Hastings JF, Han JZR, Shearer RF, Kennedy SP, Iconomou M, Saunders DN, Croucher DR.

J Vis Exp. 2018 Jun 15;(136). doi: 10.3791/57109.

PMID:
29985350
5.

Intravital Imaging to Monitor Therapeutic Response in Moving Hypoxic Regions Resistant to PI3K Pathway Targeting in Pancreatic Cancer.

Conway JRW, Warren SC, Herrmann D, Murphy KJ, Cazet AS, Vennin C, Shearer RF, Killen MJ, Magenau A, Mélénec P, Pinese M, Nobis M, Zaratzian A, Boulghourjian A, Da Silva AM, Del Monte-Nieto G, Adam ASA, Harvey RP, Haigh JJ, Wang Y, Croucher DR, Sansom OJ, Pajic M, Caldon CE, Morton JP, Timpson P.

Cell Rep. 2018 Jun 12;23(11):3312-3326. doi: 10.1016/j.celrep.2018.05.038.

6.

MASTL overexpression promotes chromosome instability and metastasis in breast cancer.

Rogers S, McCloy RA, Parker BL, Gallego-Ortega D, Law AMK, Chin VT, Conway JRW, Fey D, Millar EKA, O'Toole S, Deng N, Swarbrick A, Chastain PD, Cesare AJ, Timpson P, Caldon CE, Croucher DR, James DE, Watkins DN, Burgess A.

Oncogene. 2018 Aug;37(33):4518-4533. doi: 10.1038/s41388-018-0295-z. Epub 2018 May 10.

7.

The extracellular matrix as a key regulator of intracellular signalling networks.

Hastings JF, Skhinas JN, Fey D, Croucher DR, Cox TR.

Br J Pharmacol. 2019 Jan;176(1):82-92. doi: 10.1111/bph.14195. Epub 2018 Apr 19. Review.

8.

Axl-EGFR receptor tyrosine kinase hetero-interaction provides EGFR with access to pro-invasive signalling in cancer cells.

Vouri M, Croucher DR, Kennedy SP, An Q, Pilkington GJ, Hafizi S.

Oncogenesis. 2016 Oct 24;5(10):e266. doi: 10.1038/oncsis.2016.66.

9.

The Under-Appreciated Promiscuity of the Epidermal Growth Factor Receptor Family.

Kennedy SP, Hastings JF, Han JZ, Croucher DR.

Front Cell Dev Biol. 2016 Aug 22;4:88. doi: 10.3389/fcell.2016.00088. eCollection 2016. Review.

10.

Bimolecular complementation affinity purification (BiCAP) reveals dimer-specific protein interactions for ERBB2 dimers.

Croucher DR, Iconomou M, Hastings JF, Kennedy SP, Han JZ, Shearer RF, McKenna J, Wan A, Lau J, Aparicio S, Saunders DN.

Sci Signal. 2016 Jul 12;9(436):ra69. doi: 10.1126/scisignal.aaf0793.

PMID:
27405979
11.

PP1 initiates the dephosphorylation of MASTL, triggering mitotic exit and bistability in human cells.

Rogers S, Fey D, McCloy RA, Parker BL, Mitchell NJ, Payne RJ, Daly RJ, James DE, Caldon CE, Watkins DN, Croucher DR, Burgess A.

J Cell Sci. 2016 Apr 1;129(7):1340-54. doi: 10.1242/jcs.179754. Epub 2016 Feb 12.

12.

Intravital FRAP Imaging using an E-cadherin-GFP Mouse Reveals Disease- and Drug-Dependent Dynamic Regulation of Cell-Cell Junctions in Live Tissue.

Erami Z, Herrmann D, Warren SC, Nobis M, McGhee EJ, Lucas MC, Leung W, Reischmann N, Mrowinska A, Schwarz JP, Kadir S, Conway JRW, Vennin C, Karim SA, Campbell AD, Gallego-Ortega D, Magenau A, Murphy KJ, Ridgway RA, Law AM, Walters SN, Grey ST, Croucher DR, Zhang L, Herzog H, Hardeman EC, Gunning PW, Ormandy CJ, Evans TRJ, Strathdee D, Sansom OJ, Morton JP, Anderson KI, Timpson P.

Cell Rep. 2016 Jan 5;14(1):152-167. doi: 10.1016/j.celrep.2015.12.020. Epub 2015 Dec 24.

13.

Signaling pathway models as biomarkers: Patient-specific simulations of JNK activity predict the survival of neuroblastoma patients.

Fey D, Halasz M, Dreidax D, Kennedy SP, Hastings JF, Rauch N, Munoz AG, Pilkington R, Fischer M, Westermann F, Kolch W, Kholodenko BN, Croucher DR.

Sci Signal. 2015 Dec 22;8(408):ra130. doi: 10.1126/scisignal.aab0990.

PMID:
26696630
14.

Computational survey of peptides derived from disulphide-bonded protein loops that may serve as mediators of protein-protein interactions.

Duffy FJ, Devocelle M, Croucher DR, Shields DC.

BMC Bioinformatics. 2014 Sep 17;15:305. doi: 10.1186/1471-2105-15-305.

15.

t-PA, but not desmoteplase, induces plasmin-dependent opening of a blood-brain barrier model under normoxic and ischaemic conditions.

Freeman R, Niego B, Croucher DR, Pedersen LO, Medcalf RL.

Brain Res. 2014 May 27;1565:63-73. doi: 10.1016/j.brainres.2014.03.027. Epub 2014 Mar 25.

PMID:
24675027
16.

Temporal regulation of EGF signalling networks by the scaffold protein Shc1.

Zheng Y, Zhang C, Croucher DR, Soliman MA, St-Denis N, Pasculescu A, Taylor L, Tate SA, Hardy WR, Colwill K, Dai AY, Bagshaw R, Dennis JW, Gingras AC, Daly RJ, Pawson T.

Nature. 2013 Jul 11;499(7457):166-71. doi: 10.1038/nature12308.

17.

Involvement of Lyn and the atypical kinase SgK269/PEAK1 in a basal breast cancer signaling pathway.

Croucher DR, Hochgräfe F, Zhang L, Liu L, Lyons RJ, Rickwood D, Tactacan CM, Browne BC, Ali N, Chan H, Shearer R, Gallego-Ortega D, Saunders DN, Swarbrick A, Daly RJ.

Cancer Res. 2013 Mar 15;73(6):1969-80. doi: 10.1158/0008-5472.CAN-12-1472. Epub 2013 Feb 1.

18.

Crosstalk and signaling switches in mitogen-activated protein kinase cascades.

Fey D, Croucher DR, Kolch W, Kholodenko BN.

Front Physiol. 2012 Sep 18;3:355. doi: 10.3389/fphys.2012.00355. eCollection 2012.

19.

Functional characterization of cancer-associated Gab1 mutations.

Ortiz-Padilla C, Gallego-Ortega D, Browne BC, Hochgräfe F, Caldon CE, Lyons RJ, Croucher DR, Rickwood D, Ormandy CJ, Brummer T, Daly RJ.

Oncogene. 2013 May 23;32(21):2696-702. doi: 10.1038/onc.2012.271. Epub 2012 Jul 2.

PMID:
22751113
20.

Signalling by protein phosphatases and drug development: a systems-centred view.

Nguyen LK, Matallanas D, Croucher DR, von Kriegsheim A, Kholodenko BN.

FEBS J. 2013 Jan;280(2):751-65. doi: 10.1111/j.1742-4658.2012.08522.x. Epub 2012 Mar 14. Review.

21.

Dependence on endocytic receptor binding via a minimal binding motif underlies the differential prognostic profiles of SerpinE1 and SerpinB2 in cancer.

Cochran BJ, Croucher DR, Lobov S, Saunders DN, Ranson M.

J Biol Chem. 2011 Jul 8;286(27):24467-75. doi: 10.1074/jbc.M111.225706. Epub 2011 May 23.

22.

Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells.

Hochgräfe F, Zhang L, O'Toole SA, Browne BC, Pinese M, Porta Cubas A, Lehrbach GM, Croucher DR, Rickwood D, Boulghourjian A, Shearer R, Nair R, Swarbrick A, Faratian D, Mullen P, Harrison DJ, Biankin AV, Sutherland RL, Raftery MJ, Daly RJ.

Cancer Res. 2010 Nov 15;70(22):9391-401. doi: 10.1158/0008-5472.CAN-10-0911. Epub 2010 Sep 21.

23.

Differential endocytosis of tissue plasminogen activator by serpins PAI-1 and PAI-2 on human peripheral blood monocytes.

Lee JA, Croucher DR, Ranson M.

Thromb Haemost. 2010 Dec;104(6):1133-42. doi: 10.1160/TH10-02-0121. Epub 2010 Sep 13.

PMID:
20838737
24.

Cortactin modulates RhoA activation and expression of Cip/Kip cyclin-dependent kinase inhibitors to promote cell cycle progression in 11q13-amplified head and neck squamous cell carcinoma cells.

Croucher DR, Rickwood D, Tactacan CM, Musgrove EA, Daly RJ.

Mol Cell Biol. 2010 Nov;30(21):5057-70. doi: 10.1128/MCB.00249-10. Epub 2010 Aug 30.

25.

Overexpression of the oncogenic signal transducer Gab2 occurs early in breast cancer development.

Fleuren ED, O'Toole S, Millar EK, McNeil C, Lopez-Knowles E, Boulghourjian A, Croucher DR, Schramek D, Brummer T, Penninger JM, Sutherland RL, Daly RJ.

Int J Cancer. 2010 Sep 1;127(6):1486-92. doi: 10.1002/ijc.25172.

26.

Nedd4 controls animal growth by regulating IGF-1 signaling.

Cao XR, Lill NL, Boase N, Shi PP, Croucher DR, Shan H, Qu J, Sweezer EM, Place T, Kirby PA, Daly RJ, Kumar S, Yang B.

Sci Signal. 2008 Sep 23;1(38):ra5. doi: 10.1126/scisignal.1160940.

27.
28.

Revisiting the biological roles of PAI2 (SERPINB2) in cancer.

Croucher DR, Saunders DN, Lobov S, Ranson M.

Nat Rev Cancer. 2008 Jul;8(7):535-45. doi: 10.1038/nrc2400. Epub 2008 Jun 12. Review.

PMID:
18548086
29.

A structural basis for differential cell signalling by PAI-1 and PAI-2 in breast cancer cells.

Croucher DR, Saunders DN, Stillfried GE, Ranson M.

Biochem J. 2007 Dec 1;408(2):203-10.

30.

Preclinical evaluation of 213Bi-labeled plasminogen activator inhibitor type 2 in an orthotopic murine xenogenic model of human breast carcinoma.

Stutchbury TK, Al-Ejeh F, Stillfried GE, Croucher DR, Andrews J, Irving D, Links M, Ranson M.

Mol Cancer Ther. 2007 Jan;6(1):203-12.

Supplemental Content

Loading ...
Support Center